Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aliment Pharmacol Ther 2011; 34: 374–383 Summary: Background Imbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome (IBS). Aim To explore select bacteriological and anti‐inflammatory effects of mesalazine (mesalamine; 5‐aminosalicylic acid or 5ASA) and their relation to potential therapeutic effects in IBS. Methods Prospective pilot study of 12 women with diarrhoea‐predominant IBS. Patients received oral mesalazine (1.5 g b.d.) for 4 weeks followed by a 4‐week washout phase. Molecular profiling of stool bacterial communities and IBS symptoms were assessed before, during and after mesalazine treatment. Colonic mucosal biopsies were assessed for proteolytic activity. Qualitative and quantitative effects of mesalazine on stool microbiota, mucosal proteolytic activity and IBS symptoms were assessed. Results Faecal bacteria decreased by 46% on mesalazine treatment (P = 0.014), but returned to baseline during washout. Firmicutes and Bacteroidetes represented 95% of identified phylotypes, with a trend towards an increase in the proportion of Firmicutes at week 4 in symptomatic responders [median (IQR) 14% (49) increase] compared with nonresponders [median 5% (11) decrease, P = 0.088]. Rectosigmoid mucosal proteolytic activity did not change between baseline and treatment [median 23.2 (17.9) vs. 19.5 (46.7) mU activity/mg tissue, P = 0.433]. Eight of 12 (67%) patients responded favourably to mesalazine based on a global relief questionnaire, with significant decreases in days with discomfort and increases in bowel movement satisfaction. Conclusions Mesalazine treatment is associated with a decrease in faecal bacteria abundance and rebalancing of the major constituents of the microbiota. Further study of the bacteriological and anti‐inflammatory properties of mesalazine in IBS is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 1×
“Furthermore, treatment with the non-absorbable antibiotic rifaximin has been recently shown to improve symptoms in nonconstipation IBS in randomised studies.(11) A number of immunological abnormalities of uncertain significance have been described in populations with IBS, among them elevated numbers of colonic mucosal…”
BackgroundKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Zoetendal, E. G., von Wright, A., Vilpponen-Salmela, T., Ben-Amor, K., Akkermans, A. D. L., & de Vos, W. M. (2002) · Applied and Environmental Microbiology · doi:10.1128/aem.68.7.3401-3407.2002 · Cited by 868
Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome
Barbara, G., Wang, B., Stanghellini, V., de Giorgio, R., Cremon, C., Di Nardo, G., Trevisani, M., Campi, B., Geppetti, P., Tonini, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.039 · Cited by 783
Dysbiosis in inflammatory bowel disease
Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004) · Gut · doi:10.1136/gut.53.1.1 · Cited by 743
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Cited by
Gut microbiota in the pathogenesis of inflammatory bowel disease
Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2018) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-017-0813-5 · Cited by 1,377
The gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804
Kummen, M., Holm, K., Anmarkrud, J. A., Nygård, S., Vesterhus, M., Høivik, M. L., Trøseid, M., Marschall, H.-U., Schrumpf, E., Moum, B., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310500 · Cited by 426
Regulation of Obesity-Related Insulin Resistance with Gut Anti-inflammatory Agents
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo, X. S., Lei, H., Luk, C. T., Shi, S. Y., Surendra, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.001 · Cited by 368
Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330
Metadata
- Authors
- Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., & Rioux, K. P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-06-14
- Volume
- 34
- Issue
- 3
- Pages
- 374-383
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1549133315
- Cited by
- 97
- References
- 18
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04732.x
- The paper
- Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., & Rioux, K. P. (2011). Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04732.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.